Fate Therapeutics (FATE) vs Upstream Bio (UPB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Fate Therapeutics (FATE) has outperformed Upstream Bio (UPB) over the past year, gaining 54.7% versus a loss of 75.3%. Fate Therapeutics is the larger company by market cap ($255.2 million vs $249.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FATE | UPB |
|---|---|---|
| Share price | $2.13 | $4.55 |
| Market cap | $255.22M | $249.21M |
| 1-day change | -0.93% | -1.30% |
| YTD return | +119.39% | -83.02% |
| 1-year return | +54.68% | -75.31% |
| 5-year return | -96.49% | — |
| EPS (TTM) | $-1.05 | $-2.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.23 | $33.68 |
| 52-week low | $0.95 | $4.37 |
| Distance from 52-week high | -34.06% | -86.49% |
| Analyst consensus | buy | none |
| Avg. price target upside | +169.48% | +584.40% |
| Average volume | 1.89M | 610.08K |
| Shares outstanding | 119.82M | 54.77M |
| Employees | 161 | 75 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FATE has outperformed UPB by 130.0 percentage points over the past year.
About Fate Therapeutics
FATE stock →Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 161 employees
About Upstream Bio
UPB stock →Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
FATE vs UPB FAQ
Which is bigger, Fate Therapeutics or Upstream Bio?
Fate Therapeutics (FATE) is larger, with a market capitalization of $255.22M compared with $249.21M for Upstream Bio (UPB).
Which stock has performed better over the past year, FATE or UPB?
FATE returned +54.68% over the past 12 months, compared with -75.31% for UPB (price return, excluding dividends). Past performance does not predict future results.
Are Fate Therapeutics and Upstream Bio in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Fate Therapeutics and Biotechnology: Pharmaceutical Preparations for Upstream Bio.